Isoform selective HDAC inhibitors
US8653278B2 · kind B2 · utility
5Cited by
0References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 2, 2007 |
| Grant date | Feb 18, 2014 |
| Priority date | — |
| Expiry date | Oct 19, 2027 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
One aspect of the invention relates to isoform-selective HDAC inhibitors. Also provided are methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy. The invention also provides methods for treating cancer, methods for treating neurological diseases and methods for treating malaria. Additionally, the invention provides pharmaceutical compositions comprising an HDAC inhibitor of the invention; and kits comprising an HDAC inhibitor of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.